Compare MOMO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOMO | CRVS |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2014 | 2016 |
| Metric | MOMO | CRVS |
|---|---|---|
| Price | $5.89 | $15.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.20 |
| AVG Volume (30 Days) | 753.8K | ★ 1.1M |
| Earning Date | 03-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.65 | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.98 |
| 52 Week High | $9.22 | $26.95 |
| Indicator | MOMO | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 49.41 |
| Support Level | $5.69 | $12.95 |
| Resistance Level | $7.14 | $18.73 |
| Average True Range (ATR) | 0.13 | 0.88 |
| MACD | 0.04 | 0.23 |
| Stochastic Oscillator | 31.50 | 67.94 |
Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.